Nanotechnology Now - Press Release: Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes

Home > Press > Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes

Abstract:
A joint research team led by Professor Kyungmoo Yea from the Department of New Biology and Professor Daeha Seo from the Department of Chemistry and Physics at DGIST (President Kunwoo Lee) has developed a modular protein adapter technology that enables the stable attachment of various substances to the surface of extracellular vesicles (exosomes). This study was conducted in collaboration with Professor Moon-chang Baek’s team from the School of Medicine at Kyungpook National University. It was designed to enable functional molecules to bind efficiently, even in the complex environments of cell membranes. The research demonstrated potential for the development of tailored therapeutics.

Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes

Daegu, Republic of Korea | Posted on April 25th, 2025

Exosomes play a crucial role in intercellular signaling and have attracted attention as next-generation drug delivery carriers due to their naturally occurring properties in the body. However, conventional methods of modifying the surface of exosomes through chemical reactions carry the risk of structural damage or functional degradation. Moreover, these methods have limitations in accurately quantifying the attached substances.

□ To overcome these limitations, the research team has developed a protein adapter-based platform technology. This newly developed technology is designed to stably attach various functional substances to the surface of exosomes without directly modifying their surfaces. Experimental results confirmed the feasibility of producing tailored exosomes using this approach.

□ In addition, the team successfully quantified the amount of drug attached to individual exosomes using super-resolution microscopy. This achievement helps address the lack of quantitative analysis methods in conventional drug development and enhances the clinical applicability of exosome-based therapeutics. In particular, the team demonstrated that exosomes conjugated with antibodies can effectively target cancer cells and improve anticancer efficacy.

□ Professor Kyungmoo Yea of DGIST stated, “This research brings us closer to developing next-generation therapeutics using exosomes. We expect this platform technology, which supports the modular assembly of functional elements, to facilitate the development of therapeutics optimized for various diseases.”

□ This research was supported by the Mid-Career Research Program, the Science Research Center (SRC), the Bio & Medical Technology Development Program of the Ministry of Science and ICT, and the National Research Foundation of Korea, as well as the DGIST Grand Challenge Research Innovation Project (D-GRIP). The findings were published in ACS Nano, a prestigious nanoscience journal, where the study was selected as a supplementary cover article.

- Corresponding Author E-mail Address:

####

For more information, please click here

Contacts:
Wankyu Lim
DGIST (Daegu Gyeongbuk Institute of Science and Technology)

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: